Related Experiment Video

Updated: Aug 13, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Genotoxicity of etoposide: greater susceptibility of MLL than other target genes

A Ng1, G M Taylor, O B Eden

  • 1Immunogenetics Laboratory, University of Manchester, Oxford Road, Manchester, UK M13 3PL. antng@blueyonder.co.uk

Cancer Genetics and Cytogenetics
|January 26, 2006
PubMed

Insights

Etoposide, a topoisomerase 2 inhibitor, causes DNA breakage. The MLL gene is more susceptible to etoposide-induced cleavage than RUNX1 and MLLT3, potentially explaining MLL's role in therapy-related leukemia.

Area of Science:

  • Molecular biology
  • Genetics
  • Cancer research

Background:

  • Topoisomerase 2 inhibitors are known to cause DNA breaks.
  • Previous research focused on the impact of these inhibitors on individual genes.
  • The role of specific gene alterations in therapy-related leukemogenesis requires further investigation.

Purpose of the Study:

  • To simultaneously investigate the effects of etoposide on MLL, RUNX1, and MLLT3 genes.
  • To compare the susceptibility of MLL, RUNX1, and MLLT3 to etoposide-induced DNA cleavage.
  • To explore the potential link between MLL gene susceptibility and its involvement in treatment-related leukemogenesis.

Main Methods:

  • Simultaneous analysis of etoposide's effects on MLL, RUNX1, and MLLT3 genes.
  • Utilizing a single hemopoietic cell population for comparative gene analysis.
  • Assessing gene cleavage levels across various etoposide concentrations.

Main Results:

  • MLL demonstrated higher susceptibility to etoposide-induced DNA cleavage compared to RUNX1 and MLLT3.
  • Maximum MLL gene cleavage occurred at a lower etoposide concentration.
  • Elevated MLL cleavage levels were consistently observed across all tested drug concentrations.

Conclusions:

  • MLL exhibits greater susceptibility to topoisomerase 2 inhibitor-induced DNA cleavage.
  • This heightened susceptibility may contribute to the more frequent involvement of the MLL gene in therapy-related leukemogenesis.
  • Findings provide insights into the mechanisms underlying treatment-induced secondary malignancies.

More Related Videos

Proximity Ligand Assay to Localize Proteins in DNA Damage Sites09:39

Proximity Ligand Assay to Localize Proteins in DNA Damage Sites

Published on: August 2, 2024

Detection of DNA Double-Stranded Breaks in Mouse Oocytes07:46

Detection of DNA Double-Stranded Breaks in Mouse Oocytes

Published on: June 23, 2023

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...